Skip to content

Effectiveness of Prism Spectacles in Patients With Age Related Macular Degeneration

Effectiveness of Prism Spectacles in Patients With Age Related Macular Degeneration

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05437302
Enrollment
80
Registered
2022-06-29
Start date
2021-10-04
Completion date
2022-05-31
Last updated
2022-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Brief summary

A study is conducted to determine the effectiveness of prism spectacles in improving visual acuity with age related macular degeneration patients and to assess the improvement in quality of life in patients by using prism spectacles.

Detailed description

A random sampling technique will be used to allocate patient in interventional and non-interventional group. The diagnosed patients of age-related macular degeneration are assessed for prism spectacles for near vision and prism glasses will be dispensed to the patients. Each subject will be interviewed to fill the Proforma after taking the informed consent. The results of this study will show the effectiveness of prism glasses in patients with age related macular degeneration in their daily routine near work as compared to conventional glasses.

Interventions

DEVICEprism spectacle

a prism is dispensed in prescription glasses

Sponsors

University of Faisalabad
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients having age \>50 years with age related macular degeneration. * Patients of both genders (male and female). * Participants who will be willing to give informed consent for participation in the study.

Exclusion criteria

* Presence of all ocular disease and systemic ocular pathologies able to impair visual function. * Presence of disorders causing choroidal neovascularization other than age related macular degeneration. * Patients with mental illness, dementia, and severe physical limitations

Design outcomes

Primary

MeasureTime frameDescription
Visual AcuityFour weekNear and Distance visual acuity are measured in log Mar units.
Visual Functional Quality of life (VFQOL)Four weeksVFQOL is measured by a validated tool VFQOL-25.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026